Cargando…

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

BACKGROUND: Therapy for Type 2 diabetes (T2D) has been transformed by the introduction of newer agents like Glucagon like Peptide Receptor Agonists (GLP-1RA) and Sodium-glucose linked transporter inhibitors (SGLT2i). However with co-initiation of SGLT2i and GLP-1RA in the DURATION 8 trial an improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosal, S., Sinha, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941332/ https://www.ncbi.nlm.nih.gov/pubmed/29760945 http://dx.doi.org/10.1186/s40842-018-0061-8

Ejemplares similares

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
por: Tanaka, Kenichi, et al.
Publicado: (2022)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
por: Chua, Marvin Wei Jie
Publicado: (2021)

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months
por: Guerci, Bruno, et al.
Publicado: (2022)

Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
por: Sanyal, Debmalya, et al.
Publicado: (2013)

Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting
por: Kesavadev, Jothydev, et al.
Publicado: (2012)

Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
por: Lorenzi, Maria, et al.
Publicado: (2016)

Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
por: Kaur, Parjeet, et al.
Publicado: (2016)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
por: Tamez-Perez, Héctor Eloy, et al.
Publicado: (2017)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus
por: Taheri, Saeed, et al.
Publicado: (2019)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
por: Du, Juan, et al.
Publicado: (2023)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
por: Sinha, Binayak, et al.
Publicado: (2019)

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
por: Jeong, Su Jin, et al.
Publicado: (2021)

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
por: Nagaike, Hiroe, et al.
Publicado: (2019)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
por: Ryan, Patrick B., et al.
Publicado: (2018)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)

What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
por: Evans, Marc, et al.
Publicado: (2019)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee, Jiwoo, et al.
Publicado: (2019)

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States
por: Mody, Reema, et al.
Publicado: (2019)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
por: Chang, Kai-Cheng, et al.
Publicado: (2020)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
por: Chanawong, Apichaya, et al.
Publicado: (2023)

Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study
por: Yoo, Jee Hee, et al.
Publicado: (2019)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world
por: Marx, Nikolaus, et al.
Publicado: (2023)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
por: Uitrakul, Suriyon, et al.
Publicado: (2022)

SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
por: Sung, Jasper, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t6rgjhkq29l9c8aj82imgcgesk